ID

Invicta Diagnostic Ltd

Q2 FY27Healthcare Services

Invicta Diagnostic Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Invicta Diagnostic Ltd Q2 FY27 key numbers

Revenue
Year-on-year change in revenue: Increase of approximately ₹272.87 lakhs.

As stated in Invicta Diagnostic Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Invicta Diagnostic Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹83
Market cap₹104 Cr
P/E23.4

The short version

Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). EBITDA for the quarter: ₹540.8 Lakhs, a 9.5% year-on-year (YoY) increase.

From Invicta Diagnostic Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Invicta Diagnostic's revenue grow in the September 2026 quarter?

  • Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4).
  • Corresponding half year ended September 30, 2025: ₹106.24 lakhs (Page 4).
  • Year-on-year change in revenue: Increase of approximately ₹272.87 lakhs.
  • The company operates in a single business segment providing diagnostic services and derives some revenue from customers outside India (Page 12).

What happened to Invicta Diagnostic's margins in Q2 FY27?

EBITDA for the quarter: ₹540.8 Lakhs, a 9.5% year-on-year (YoY) increase.

Locked: what Invicta Diagnostic Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Invicta Diagnostic planning?

  • The IPO proceeds include Rs. 1,351.33 Lakhs allocated (revised at EGM on April 17, 2026) towards capital expenditure to commence at least five diagnostic centres in Maharashtra, either directly or through subsidiary entities.
  • Cumulative utilization of this capex allocation up to September 30, 2026, is Rs. 775.36 Lakhs, leaving Rs. 575.97 Lakhs unutilized.
  • An unutilized amount of Rs. 15.10 Lakhs from issue-related expenses was reallocated to General Corporate Purposes.
  • The variation in utilization and change in objects was approved by shareholders on April 17, 2026.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Invicta Diagnostic raising money or cutting debt?

The investor presentation indicates fundraising through an Initial Public Offer (IPO) with gross proceeds…

Locked: what Invicta Diagnostic Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

How big is Invicta Diagnostic's order book?

See what Invicta Diagnostic Ltd said on order book & pipeline — free account, 30 seconds.

More Q2 FY27 results in Healthcare Services

All Q2 FY27 results | Healthcare Services rankings

What Invicta Diagnostic's management said in earlier quarters

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Revenue from operations for the half year ended 30th September 2026 is ₹10,660.84 lakhs, compared to the previous year ended 31st March 2026 figure of…

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Health X Platform (Q2 FY27)

    Q2 FY27 revenue from operations: Rs 489.1 Cr, up 58.8% year-on-year (Page 24). Key investor presentation takeaways from Health X Platform Ltd's Q2 FY27 investor

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Invicta Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Invicta Diagnostic Ltd Q2 FY27 results?

Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). EBITDA for the quarter: ₹540.8 Lakhs, a 9.5% year-on-year (YoY) increase.

What is Invicta Diagnostic Ltd share price analysis?

Invicta Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 23.4 with a market cap of ₹104 Cr. Investors should review the full earnings analysis for detailed insights.

Is Invicta Diagnostic Ltd planning capital expenditure?

The IPO proceeds include Rs. 1,351.33 Lakhs allocated (revised at EGM on April 17, 2026) towards capital expenditure to commence at least five diagnostic centres in Maharashtra, either directly or thr.

Keep Invicta Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.